Considering that PD-L1 expression is correlated with a poor prognostic in melanoma [38,39], that despite very promising clinical results, at best, 40% of metastatic melanoma patients objectively respond to ICI therapy targeting either PD-1 or PD-L1 [40,41], and that PD-L1 expression in the tumor and its stroma makes it a most interesting target for TAT, the aim of this study was to develop and investigate TAT using 213Bi-anti-PD-L1 mAb in a preclinical model of human melanoma. The gene discussed is CD274; the disease is neoplasm.